Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732052 | PMC |
| http://dx.doi.org/10.1093/cid/cis960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION.
Arq Gastroenterol
January 2025
Universidade Federal de São Paulo, São Paulo, SP, Brasil.
Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).
View Article and Find Full Text PDFMolecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
Diagnostics (Basel)
September 2023
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65522, Saudi Arabia.
Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide. Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option. However, amino acid substitution-dependent resistance to DAAs has been a major challenge.
View Article and Find Full Text PDFClinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
PLoS One
December 2022
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Article Synopsis
- - The study evaluated the effectiveness of Sofosbuvir (SOF)-based treatments for chronic hepatitis C in Spain from 2015-2019, showing improved patient outcomes compared to older therapies like peginterferon and ribavirin.
- - SOF-based regimens yielded a sustained virological response (SVR) of 93-98% and significantly reduced complications such as decompensated cirrhosis (by 89%) and liver-related mortality (by 82%), while also providing substantial cost savings.
- - Overall, the findings support SOF-based treatments as a cost-effective solution that enhances health outcomes for HCV patients in Spain, aligning with global health objectives set by the WHO.
Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase.
ACS Omega
October 2022
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research; Drug Discovery Institute; Departments of Computational Biology and Structural Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Transmissible and infectious viruses can cause large-scale epidemics around the world. This is because the virus can constantly mutate and produce different variants and subvariants to counter existing treatments. Therefore, a variety of treatments are urgently needed to keep up with the mutation of the viruses.
View Article and Find Full Text PDFFrom Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Molecules
July 2022
Institute of Molecular Medicine, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany.
The main protease (M) of the betacoronavirus SARS-CoV-2 is an attractive target for the development of treatments for COVID-19. Structure-based design is a successful approach to discovering new inhibitors of the M. Starting from crystal structures of the M in complexes with the Hepatitis C virus NS3/4A protease inhibitors boceprevir and telaprevir, we optimized the potency of the alpha-ketoamide boceprevir against the M by replacing its P1 cyclobutyl moiety by a γ-lactam as a glutamine surrogate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!